Loretta Nastoupil, MD, and John Burke, MD, discuss the therapeutic landscape for patients with transplant-ineligible, relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and begin with an overview of the disease.
CD19 As a Therapeutic Target In Diffuse Large B-Cell Lymphoma
Loretta Nastoupil, MD, and John Burke, MD, provide an overview of different prognostic factors that have been identified in diffuse large B-cell lymphoma (DLBCL).
Loretta Nastoupil, MD, and John Burke, MD, provide insight into treating patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Loretta Nastoupil, MD, and John Burke, MD, discuss transplant as a treatment option for patients with relapsed/refractory [R/R] diffuse large B-cell lymphoma [DLBCL], as well as treatment options for patients with relapsed disease after transplant.
Insight into the combination of tafasitamab plus lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Loretta Nastoupil, MD, and John Burke, MD, review data from the L-MIND study presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
An overview of CD19 as a treatment target for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Experts discuss tafasitamab, a CD19-targeted monoclonal antibody (mAb) for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Experts discuss the LOTIS-2 trial that studied loncastuximab tesirine, a CD19-targeted monoclonal antibody for treating patients with relapsed/refractory diffuse large B-cell lymphoma.
Loretta Nastoupil, MD, and John Burke, MD, discuss the future of the therapeutic landscape for patients with transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma.